Find a Clinical Trial
Is a clinical trial right for you? Search our database to find studies for which you may be eligible.
A phase I/II trial of Rucaparib in combination with Ramucirumab with or without Nivolumab in previously treated patients with advanced gastric and esophageal adenocarcinoma RiME
A Phase II, Open-Label, Single-Arm Trial of [Fam]-Trastuzumab Deruxtecan DS-8201a in HER2-Positive, Unresectable and/or Metastatic Gastric or Gastro-Esophageal Junction GEJ Adenocarcinoma Subjects Who Have Progressed On or After A Trastuzumab-Containing Regimen
A Randomized, Double-blind, Placebo-controlled Phase III Trial of Pembrolizumab MK-3475 Versus Placebo in Participants with Esophageal Carcinoma Receiving Concurrent Definitive Chemoradiotherapy KEYNOTE 975
Phase I Trial with Expansion Cohort of OBP-301 Telomelysin and Definitive Chemoradiation for Patients with Locally Advanced Esophageal and Gastroesophageal Adenocarcinoma Who Are Not Candidates for Surgery
A Phase III, Global, Multi-Center, Double-Blind, Randomized, Efficacy Study of Zolbetuximab IMAB362 Plus CAPOX Compared with Placebo Plus CAPOX as First-line Treatment of Subjects with Claudin CLDN18.2-Positive, HER2-Negative, Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction GEJ Adenocarcinoma
Randomized Phase III Trial of Mfolfirnox +/- Nivolumab Vs. Folfox +/- Nivolumab for First-line Treatment of Metastatic HER2-Negative Gastroesophageal Adenocarcinoma
A Phase II Study of Perioperative mFOLFOX Fluorouracil, Leucovorin, and Oxaliplatin Chemotherapy Plus Pembrolizumab MK-3475 Combination in Patients with Potentially Resectable Adenocarcinoma of the Gastroesophageal Junction GEJ and Stomach MISP 52216
A Phase 2 Single-Arm Study of M6620 in Combination with Irinotecan in Patients with Progressive TP53 Mutant Gastric and Gastro-Esophageal Junction Cancer
A Phase I/Ib Study of ASP2138 in Participants with Metastatic or Locally Advanced Unresectable Gastric or Gastroesophageal Junction GEJ Adenocarcinoma or Metastatic Pancreatic Adenocarcinoma Whose Tumor Have Claudin CLDN 18.2 Expression
Study Type: Treatment
Phase: I
NCTID: NCT05365581
Principal Investigator:
Anup Kasi